Literature DB >> 10981172

Mechanism of differential effects of antihypertensive agents on serum lipids.

R D Brook1.   

Abstract

Essential hypertension is frequently associated with the metabolic abnormalities of insulin resistance and dyslipidemia. This prevalent clustering of multiple cardiovascular risk factors may help explain the less-than-expected improvement in coronary heart disease mortality provided by simple blood pressure reduction alone. Many antihypertensive medications effectively reduce blood pressure while providing no benefit or even causing a detrimental effect on the associated metabolic abnormalities. beta-Blockers and diuretics tend to negatively affect both glucose tolerance and plasma lipids. Calcium channel blockers, angiotensin converting enzyme inhibitors, and angiotensin II receptor blockers are most often found to be metabolically neutral. alpha-Blockers provide the most favorable metabolic effects of antihypertensive agents by improving both insulin sensitivity and dyslipidemia. The multiple physiologic mechanisms by which blood pressure medications alter plasma lipids are discussed in detail. The effects of antihypertensive medications on postprandial lipid metabolism and the associated postprandial lipemia-induced endothelial dysfunction deserve special attention.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10981172     DOI: 10.1007/s11906-000-0040-0

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  47 in total

1.  Impaired postprandial tissue regulation of blood flow in insulin resistance: a determinant of cardiovascular risk?

Authors:  L K Summers; J S Samra; K N Frayn
Journal:  Atherosclerosis       Date:  1999-11-01       Impact factor: 5.162

2.  Effect of a single high-fat meal on endothelial function in healthy subjects.

Authors:  R A Vogel; M C Corretti; G D Plotnick
Journal:  Am J Cardiol       Date:  1997-02-01       Impact factor: 2.778

3.  Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.

Authors:  T Pollare; H Lithell; I Selinus; C Berne
Journal:  BMJ       Date:  1989-04-29

4.  Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on postprandial endothelial function.

Authors:  H W Wilmink; J D Banga; M Hijmering; W D Erkelens; E S Stroes; T J Rabelink
Journal:  J Am Coll Cardiol       Date:  1999-07       Impact factor: 24.094

5.  Insulin-independent diabetes: a defect in the activity of lipoprotein lipase in adipose tissue.

Authors:  K G Taylor; D J Galton; G Holdsworth
Journal:  Diabetologia       Date:  1979-05       Impact factor: 10.122

Review 6.  Decreased peripheral blood flow in the pathogenesis of the metabolic syndrome comprising hypertension, hyperlipidemia, and hyperinsulinemia.

Authors:  L Lind; H Lithell
Journal:  Am Heart J       Date:  1993-05       Impact factor: 4.749

7.  Epinephrine stimulates human muscle lipoprotein lipase activity in vivo.

Authors:  S B Pedersen; J F Bak; P Holck; O Schmitz; B Richelsen
Journal:  Metabolism       Date:  1999-04       Impact factor: 8.694

8.  Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries.

Authors:  K Kugiyama; H Doi; T Motoyama; H Soejima; K Misumi; H Kawano; O Nakagawa; M Yoshimura; H Ogawa; T Matsumura; S Sugiyama; T Nakano; K Nakajima; H Yasue
Journal:  Circulation       Date:  1998-06-30       Impact factor: 29.690

9.  Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans.

Authors:  G F Lewis; K D Uffelman; L W Szeto; B Weller; G Steiner
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

10.  Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium.

Authors:  J H Helderman; D Elahi; D K Andersen; G S Raizes; J D Tobin; D Shocken; R Andres
Journal:  Diabetes       Date:  1983-02       Impact factor: 9.461

View more
  9 in total

Review 1.  Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect?

Authors:  Paul Ernsberger; Richard J Koletsky
Journal:  Curr Opin Pharmacol       Date:  2007-02-15       Impact factor: 5.547

2.  Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X.

Authors:  Rodney A Velliquette; Rachel Kossover; Stephen F Previs; Paul Ernsberger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-01-17       Impact factor: 3.000

Review 3.  Lipid effects of antihypertensive medications.

Authors:  Roderick Deano; Matthew Sorrentino
Journal:  Curr Atheroscler Rep       Date:  2012-02       Impact factor: 5.113

Review 4.  Single-pill telmisartan and amlodipine: a rational combination for the treatment of hypertension.

Authors:  Carmen Suárez
Journal:  Drugs       Date:  2011-12-03       Impact factor: 9.546

Review 5.  Antihypertensive medications and their effects on lipid metabolism.

Authors:  Mrunalini Deshmukh; Ho Won Lee; Samy I McFarlane; Adam Whaley-Connell
Journal:  Curr Diab Rep       Date:  2008-06       Impact factor: 4.810

Review 6.  Use of carvedilol in hypertension: an update.

Authors:  Gastone Leonetti; Colin G Egan
Journal:  Vasc Health Risk Manag       Date:  2012-05-18

7.  Genome-wide meta-analysis of variant-by-diuretic interactions as modulators of lipid traits in persons of European and African ancestry.

Authors:  L de Las Fuentes; Y J Sung; C M Sitlani; C L Avery; T M Bartz; C de Keyser; D S Evans; X Li; S K Musani; R Ruiter; A V Smith; F Sun; S Trompet; H Xu; D K Arnett; J C Bis; U Broeckel; E L Busch; Y-D I Chen; A Correa; S R Cummings; J S Floyd; I Ford; X Guo; T B Harris; M A Ikram; L Lange; L J Launer; A P Reiner; K Schwander; N L Smith; N Sotoodehnia; J D Stewart; D J Stott; T Stürmer; K D Taylor; A Uitterlinden; R S Vasan; K L Wiggins; L A Cupples; V Gudnason; S R Heckbert; J W Jukema; Y Liu; B M Psaty; D C Rao; J I Rotter; B Stricker; J G Wilson; E A Whitsel
Journal:  Pharmacogenomics J       Date:  2019-12-06       Impact factor: 3.245

Review 8.  Carvedilol in hypertension treatment.

Authors:  Panagiotis C Stafylas; Pantelis A Sarafidis
Journal:  Vasc Health Risk Manag       Date:  2008

9.  Highly potent antioxidant Olea europaea L. leaf extract affects carotid and renal haemodynamics in experimental hypertension: The role of oleuropein.

Authors:  Milan Ivanov; Una-Jovana Vajic; Nevena Mihailovic-Stanojevic; Zoran Miloradovic; Djurdjica Jovovic; Jelica Grujic-Milanovic; Danijela Karanovic; Dragana Dekanski
Journal:  EXCLI J       Date:  2018-01-04       Impact factor: 4.068

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.